Get the Stockscreener App
6.05
3.60%
0.21
After Hours:
6.07
0.02
+0.33%
Ardelyx Inc stock is traded at $6.05, with a volume of 9.84M.
It is up +3.60% in the last 24 hours and down -0.98% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$5.84
Open:
$5.9
24h Volume:
9.84M
Relative Volume:
2.69
Market Cap:
$1.49B
Revenue:
$427.68M
Net Income/Loss:
$-58.06M
P/E Ratio:
-25.40
EPS:
-0.2382
Net Cash Flow:
$-37.50M
1W Performance:
+4.49%
1M Performance:
-0.98%
6M Performance:
+6.51%
1Y Performance:
+67.59%
1-Day Range:
$5.7497
$6.07
1-Week Range:
$5.575
$6.07
52-Week Range:
$3.49
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
6.05 | 1.49B | 427.68M | -58.06M | -37.50M | -0.2382 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-03-25 | Resumed | Raymond James | Strong Buy |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’ - Stocktwits
Ardelyx (ARDX) director granted RSUs and 39,715-share stock option - Stock Titan
Laura A. Williams proposes sale of 31,000 shares (ARDX) - Stock Titan
Ardelyx (ARDX) director receives 26,455 RSUs and 39,715-share option - Stock Titan
Equity grants to Ardelyx (ARDX) director under compensation program - Stock Titan
Ardelyx (ARDX) director Cadoret-Manier receives RSU and option grants - Stock Titan
Ardelyx (ARDX) director receives RSUs and stock options as compensation - Stock Titan
Ardelyx (NASDAQ: ARDX) director awarded RSUs and stock options grant - Stock Titan
Ardelyx (ARDX) director Robert Bazemore receives RSU and option awards - Stock Titan
Ardelyx Inc (ARDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ardelyx Inc (ARDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ardelyx Inc (ARDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ardelyx Inc (ARDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ardelyx shareholders approve director elections and equity plan amendment By Investing.com - Investing.com Canada
Ardelyx shareholders approve director elections and equity plan amendment - Investing.com
Ardelyx Inc (ARDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ardelyx approves Equity Plan Amendment at 2026 Annual Meeting - TradingView
Ardelyx (NASDAQ: ARDX) shareholders approve equity plan, directors and auditor at 2026 meeting - Stock Titan
Ardelyx Inc (ARDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ardelyx (ARDX) CEO trades shares under 10b5-1 plan, exercises options - Stock Titan
ARDX insider Michael G. Raab sells 179,748 shares (NASDAQ: ARDX) - Stock Titan
Ardelyx (ARDX) Stock Could Be 65% Undervalued As Growth Hopes Face Reassessment - simplywall.st
Ardelyx Inc (ARDX) Institutional Confidence - TradingKey
ARDX Assumes Buy by Ladenburg Thalmann -- Price Target Announced at $16 - GuruFocus
Ardelyx Inc (ARDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits
ARDX (NASDAQ) insider sales: 125,000 shares notice; Raab 10b5-1 trades listed - Stock Titan
ARDX edges up after hours on IBSRELA momentum and profitability 'right around the corner' - MSN
Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility - Yahoo Finance
Ardelyx eyes $500M+ revenue as IBSRELA growth puts profitability within reach - MSN
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits
Hyperphosphatemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Ardelyx, Sanofi, Takeda Pharma, Unicycive Therapeutics, Taisho Pharma, Alebund Pharma - Barchart
ARDX Q1 2026 Earnings: Earnings Miss But Stock Gains as Investors Focus on Pipeline ProgressHigh Estimate Range - newsline.com
ARDX Q1 2026 Earnings: EPS Misses Estimates Slightly, Stock Gains Amid Mixed SignalsEarnings Revision Report - newsline.com
· SEC Filing - MLQ.ai
Assessing Ardelyx (ARDX) Valuation After Recent Share Price Pullback And Growth Expectations - simplywall.st
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - TMX Newsfile
Ardelyx Advances Long-Term Tenapanor Trial in Chronic Constipation: What Investors Should Watch - TipRanks
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach - TradingView
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):